Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three years.
AbbVie Parkinson’s drug helps improve symptoms in late-stage study
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and secondary endpoints.
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).
Promising results from Parkinson’s drug trial
Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's disease and improved motor skills, the company reported on Thursday.
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.
AbbVie’s Parkinson’s Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study
AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline versus placebo in adults with early Parkinson's.
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday. Patients showed a statistically significant improvement when two fixed doses of the drug,
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a
The Pharma Letter
2d
AbbVie’s tavapadon offers encouragement in Parkinson’s
AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...
Monthly Prescribing Reference
2d
Tavapadon Improves Motor Function in Patients With Early Parkinson Disease
In the TEMPO-1 trial, participants with early PD were randomly assigned to receive tavapadon 5mg or 15mg once daily or placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Helene death toll rises
Helene: How to help
Rescue mission launched
Courthouse attack: Charged
NC dam failure ‘imminent’
High-end brothel plea
Houthis attack US warships
Troops to leave some bases
Congestion fee bid denied
Bill to use birth control
AL sued over purging voters
ICE: Convicts roaming free
Haney sues Garcia
Dow closes at record high
Van Gogh paintings attacked
Diocese reaches settlement
Meta hit with privacy fine
Human rabies death in MN
121st loss of the season
UNC digital IDs blocked
'Harry Potter' star dies
Congressional Gold Medal
Deposition in AI suit
Fed inflation gauge cools
US charges three Iranians
NY ballot appeal rejected
KY sues Express Scripts
Feedback